Clinical islet transplantation: Where immunity and metabolism intersect?

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 19, Issue 4, 2012, Pages 249-254

  Gill, Ronald G ^a   Bishop, Nicholas H ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Autoimmunity; Islet transplantation; Metabolism; Type 1 diabetes

Indexed keywords

BASILIXIMAB; EFALIZUMAB; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; TACROLIMUS;

ADAPTIVE IMMUNITY; ALLOGRAFT; DRUG MEGADOSE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; INFLAMMATION; LOW DRUG DOSE; METABOLISM; PANCREAS ISLET TRANSPLANTATION; REVIEW; T LYMPHOCYTE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; GRAFT SURVIVAL; HUMANS; INSULIN; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; METABOLIC CLEARANCE RATE; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TREATMENT OUTCOME;

EID: 84864592518     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e328355a2ec     Document Type: Review

References (47)

1. Shapiro AMJ, Lakey JRT, Ryan EA, et al. Islet transplantation in seven patients with type I diabetes mellitus using a glucocorticoid-free immunosupressive regimen. N Engl J Med 2000; 343:230-238.
2. Ryan EA, Lakey JRT, Paty BW, et al. Successful islet transplantation. Continued insulin reserve provides long-term glycemic control. Diabetes 2002; 51:2148-2157.
3. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54:2060-2069.
4. Bussiere CT, Lakey JR, Shapiro AM, Korbutt GS. The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia 2006; 49:2341-2349.
5. Zhang N, Su D, Qu S, et al. Sirolimus is associated with reduced islet engraftment and imparied b-cell function. Diabetes 2006; 55:2429-2436.
6. Tanemura M, Ohmura Y, Deguchi T, et al. Rapamcyin causes upregulation of autophagy and impairs islets function both in vitro and in vivo. Am J Transplant 2011; 12:102-114.
7. Cantaluppi V, Biancone L, Romanzzi GM, et al. Antiantiogenic and immunomodulatory effects of rapamycin on islet endothelium: relevance for islet transplantation. Am J Transplant 2006; 6:2601-2611.
8. Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by B cell regneration. J Clin Invest 2007; 117:2553-2561.
9. Shapiro AM, Ricordi C, Hering GJ, et al. International trial of the Edmonton Protocol for islet transplantation. N Engl J Med 2006; 355:1318-1330.
10. Hering BJ, Kandaswamy R, Harmon JV, et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 2004; 4:390-401.
11. Nicolls MR, Coulombe M, Yang H, et al. Anti-LFA-1 therapy induces long-term islet allograft acceptance in the absence of IFN-gamma or IL-4. J Immunol 2000; 164:3627-3634.
12. Turgeon NA, Avila JG, Cano JA, et al. Experience with a novel eflaizumabbased immunosuppressive regimen to facilitate single donor islet cell transplantation. Am J Transplant 2010; 10:2082-2091.
13. Posselt AM, Bellin MD, Tavakol M, et al. Islet transplantation in type 1 diabetic using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant 2010; 10:1870-1880.
14. Posselt AM, Szot GL, Frasseto LA, et al. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation 2010; 90:1595-1601.
15. Badell IR, Russell MC, Thompson PW, et al. LFA-1-specific therapy prolongs allograft survival in rhesus macaques. J Clin Invest 2010; 120:4520-4531.
16. Badell IR, Thompson PW, Turner AP, et al. Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates. Am J Transplant 2012; 12:126-135.
17. Badell IR, Russell MC, Cardona K, et al. CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8. Am J Transplant 2012 [Epub ahead of print].
18. Zheng XX, Sanchez-Fueyo A, Sho M, et al. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 2003; 19:503-514.
19. Koulmanda M, Qipo A, Fan Z, et al. Prolonged survival of allogeneic islets in cynomolgus monkeys after short-term triple therapy. Am J Transplant 2012 [Epub ahead of print].
20. Clinical Islet Transplant Consortium website: www.citisletstudy.org/ index.html.
21. Roep BO, Stobbe I, Duinkerken G, et al. Auto-and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes 1999; 48:484-490.
22. Roelen DL, Huurman VAL, Hilbrands R, et al. Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet transplantation. Clin Exp Immunol 2009; 156:141-148.
23. Huurman VAL, Hilbrands R, Pinkse GGM, et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS One 2008; 3:e2435.
24. Bellin MD, Sutherland DER, Beilman G, et al. Similar islet function in islet allotransplant and autotransplant recipients, despite lower islet mass in autotransplants. Transplantation 2011; 91:376-372.
25. Sutherland DER, Greussner AC, Carlson AM, et al. Islet autotransplant outcomes after total pancreatectomy: a contrast to islet allograft outcomes. Transplantation 2010; 86:1799-1802.
26. Davalli AM, Scaglia L, Zangen DH, et al. Vulnerability of islets in the immediate posttransplantation period. Dynamic changes in structure and function. Diabetes 1996; 45:1161-1167.
27. Emamaullee JA, Shapiro AM. Interventional strategies to prevent b-cell apoptosis in islet transplantation. Diabetes 2006; 55:1907-1914.
28. Ozmen L, Ekdahl KN, Elgue G, et al. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes 2002; 51:1779-1784.
29. Johansson H, Goto M, Siegbahn A, et al. Low molecular weight dextran sulfate: a strong candidate drug to block IMBIR in clinical islet transplantation. Am J Transplant 2006; 6:305-312.
30. Kruger B, Yin N, Zhang N, et al. Islet-expressed TLR2 and TLR4 sense injury and mediate early graft failure after transplantation. Eur J Immunol 2010; 40:2914-2924.
31. Gao Q, Ma LL, Gao X, et al. TLR4 mediates early graft failure after intraportal islet transplantation. Am J Transplant 2010; 10:1588-1596.
32. Matsuoka N, Itoh T, Watarai H, et al. High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice. J Clin Invest 2010; 120:735-743.
33. Steer SA, Scarim AL, Chambers KT, Corbett JA. Interleukin-1 stimulates b-cell necrosis and release of the immunological adjuvant HMGB1. PLoS Med 2006; 3:253-266.
34. Cantley J, Grey ST, Maxwell PH, Withers DJ. The hypoxia response pathway and b-cell function. Diabetes Obes Metab 2010; 12 (Suppl. 2):159-167.
35. McCall M, Pawlick R, Kin T, Shapiro AM. Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice. Am J Transplant 2012; 12:322-329.
36. Westwell-Roper C, Dai DL, Soukhatcheva G, et al. IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction. J Immunol 2011; 187:2755-2765.
37. Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 2004; 89:3629-3643.
38. Westermark GT, Westermark P, Berne C, Korsgren O. Widespread amyloid deposition in transplanted human pancreatic islets. N Engl J Med 2008; 28:977-979.
39. Westermark GT, Davalli AM, Secch A, et al. Further evidence for amyloid deposition in clinical pancreatic islet grafts. Transplantation 2012; 93:219-223.
40. Udayasankar J, Kodama K, Hull RL, et al. Amyloid formation results in recurrence of hyperglycaemia following transplantation of human IAPP transgenic mouse islets. Diabetologia 2009; 52:145-153.
41. Potter KJ, Abedini A, Marek P, et al. Islet amyloid deposition limits the viability of human islet grafts but not porcine islet grafts. Proc Natl Acad Sci USA 2010; 107:4305-4310.
42. Donath MY, Schumann DM, Faulenback M, et al. Islet inflammation in type 2 diabetes. From metablic stress to therapy. Diabetes Care 2008; 31 (Suppl. 2): S161-S164.
43. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356:1517-1526.
44. Masters SL, Dunne A, Subramanian SL, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1b in type 2 diabetes. Nat Immunol 2010; 11:897-905.
45. Cai K, Qi D, Wang O, et al. TNF-a acutely upregulates amylin expression in murine pancreatic beta cells. Diabetologia 2011; 54:617-626.
46. Grossman EJ, Lee DD, Tao J, et al. Glycemic control promotes pancreatic beta-cell regeneration in streptozotocin-induced diabetic mice. PLoS One 2010; 5:e8759.
47. Ablamunits V, Henegariu O, Hansen JB, et al. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade. Diabetes 2012; 61:145-154.